European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib

References

• TobonGJYouinouPSarauxAThe environment, geoepidemiology, and autoimmune disease: rheumatoid arthritisJ Autoimmun201035101420080387
   PubMed Web of Science ®Google Scholar
• McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
   PubMed Web of Science ®Google Scholar
• SinghJASaagKGBridgesSLJr2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritisArthritis Rheumatol201668126
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)National Collaborating Centre for Chronic ConditionsRheumatoid Arthritis: The Management of Rheumatoid Arthritis in AdultsLondon (UK)Royal College of Physicians200979
   Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisArthritis Rheum1995387277357779114
   PubMed Web of Science ®Google Scholar
• StorageSSAgrawalHFurstDEDescription of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritisKorean J Intern Med20102511720195397
   PubMedGoogle Scholar
• SmolenJSLandewéRBijlsmaJEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnn Rheum Dis201776696097728264816
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• KeystoneECKavanaughAFSharpJTRadiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialArthritis Rheum2004501400141115146409
   PubMed Web of Science ®Google Scholar
• LipskyPEvan der HeijdeDMClairEWStInfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupN Engl J Med2000343221594160211096166
   PubMed Web of Science ®Google Scholar
• KielyPDDeightonCDixeyJOstorAJBiologic agents for rheumatoid arthritis–negotiating the NICE technology appraisalsRheumatology (Oxford)2012511243122039226
   PubMed Web of Science ®Google Scholar
• VieiraMCZwillichSJansenJPSmiechowskiBSpurdenDWallensteinGVTofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysisClin Ther201638122628264127889300
   PubMed Web of Science ®Google Scholar
• KaldenJREmerging therapies for rheumatoid arthritisReumathol Ther2016313142
   PubMedGoogle Scholar
• WinthropKLThe emerging safety profile of JAK inhibitors in rheumatic diseaseNat Rev Rheumatol201713423424328250461
   PubMed Web of Science ®Google Scholar
• BlancoFJMörickeRDokoupilovaESecukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled studyArthritis Rheumatol20176961144115328217871
   PubMed Web of Science ®Google Scholar
• GenoveseMCGreenwaldMChoCSA phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsArthritis Rheumatol20146671693170424623718
   PubMed Web of Science ®Google Scholar
• TaylorPCKeystoneECvan der HeijdeDBaricitinib versus placebo or adalimumab in rheumatoid arthritisN Engl J Med201737665266228199814
   PubMed Web of Science ®Google Scholar
• TakeuchiTTanakaYIwasakiMIshikuraHSaekiSKanekoYEfficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyAnn Rheum Dis20167561057106426672064
   PubMed Web of Science ®Google Scholar
• KavanaughAKremerJPonceLFilgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)Ann Rheum Dis20177661009101927993828
   PubMed Web of Science ®Google Scholar
• AbushoukAIAhmedHIsmailASafety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to MTX or tumor necrosis factor inhibitors: a systematic review and meta-analysisRheumatol Int20173771053106428236221
   PubMed Web of Science ®Google Scholar
• KontziasALaurenceAGadinaMO’SheaJJKinase inhibitors in the treatment of immune-mediated diseaseF1000 Med Rep20124522403586
   PubMedGoogle Scholar
• MaeshimaKYamaokaKKuboSThe JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cellsArthritis Rheum20126461790179822147632
   PubMed Web of Science ®Google Scholar
• MeyerDMJessonMILiXAntiinflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJ Inflamm (Lond)201074120701804
   PubMed Web of Science ®Google Scholar
• van der HeijdeDTanakaYFleischmannRTofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving MTX twelve-month data from a twenty-four–month phase III randomized radiographic studyArthritis Rheum201365355957023348607
   PubMed Web of Science ®Google Scholar
• HodgeJAKawabataTTKrishnaswamiSThe mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritisClin Exp Rheumatol201634231832826966791
   PubMed Web of Science ®Google Scholar
• EMASummary of Product Characteristic2017 Avaliable from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004214/WC500224911.pdfAccessed September 28, 2017
   Google Scholar
• van VollenhovenRFleischmannRCohenSTofacitinib or adalimumab versus placebo in rheumatoid arthritisN Engl J Med201236750851922873531
   PubMed Web of Science ®Google Scholar
• BurmesterGRBlancoRCharles-SchoemanCHWollenhauptJTofacitinib (CP-690,550) in combination with MTX in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase III trialLancet201338145146023294500
   PubMed Web of Science ®Google Scholar
• FleischmannRCutoloMGenoveseMCPhase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsArthritis Rheum201264361762921952978
   PubMed Web of Science ®Google Scholar
• FleischmannRKremerJCushJPlacebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisN Engl J Med2012367649550722873530
   PubMed Web of Science ®Google Scholar
• FleischmannRMyslerEHallSORAL Strategy InvestigatorsEfficacy and safety of tofacitinib monotherapy, tofacitinib with MTX, and adalimumab with MTX in patients with rheumatoid arthritis (ORAL Strategy): a phase IIIb/IV, double-blind, head-to-head, randomised controlled trialLancet20173901009345746828629665
   PubMed Web of Science ®Google Scholar
• KremerJLiZGHallSTofacitinib in combination with non-biologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialAnn Intern Med2013159425326124026258
   PubMed Web of Science ®Google Scholar
• KremerJMBloomBJBreedveldFCThe safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placeboArthritis Rheum20096071895190519565475
   PubMed Web of Science ®Google Scholar
• KremerJMCohenSWilkinsonBEA phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background MTX in patients with active rheumatoid arthritis and an inadequate response to MTX aloneArthritis Rheum201264497098122006202
   PubMed Web of Science ®Google Scholar
• LeeEBFleischmannRHallSTofacitinib versus MTX in rheumatoid arthritisN Engl J Med20143702377238624941177
   PubMed Web of Science ®Google Scholar
• TanakaYSuzukiMNakamuraHToyoizumiSZwillichSHTofacitinib Study InvestigatorsPhase II study of tofacitinib (CP-690,550) combined with MTX in patients with rheumatoid arthritis and an inadequate response to MTXArthritis Care Res (Hoboken)2011631150115821584942
   PubMed Web of Science ®Google Scholar
• WollenhauptJSilverfieldJLeeEBSafety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open label, long term extension studiesJ Rheumatol20144183785224692527
   PubMed Web of Science ®Google Scholar
• YamanakaHTanakaYTakeuchiTTofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background MTX, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension studyArthritis Res Ther2016183426818974
   PubMed Web of Science ®Google Scholar
• BergrathEGerberRGrubenDTatjanaLMakinCWallensteinGTofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysisInt J Rheumatol20172017841724928377787
   PubMed Web of Science ®Google Scholar
• CohenSBTanakaYMarietteXLong-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsAnn Rheum Dis2017761253126228143815
   PubMed Web of Science ®Google Scholar
• CurtisJRSchulze-KoopsHTakiyaLEfficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisClin Exp Rheumatol201735339040028079500
   PubMed Web of Science ®Google Scholar
• CohenSRadominskiSCGomez-ReinoJJAnalysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisArthritis Rheumatol2014662924293725047021
   PubMed Web of Science ®Google Scholar
• SoutoAManeiroJRSalgadoECarmonaLGomez-ReinoJJRisk of tuberculosis in patients with chronic immunemediated infammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesRheumatology (Oxford)201453101872188524821849
   PubMed Web of Science ®Google Scholar
• WinthropKLParkSHGulATuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisAnn Rheum Dis20167561133113826318385
   PubMed Web of Science ®Google Scholar
• WinthropKLYamanakaHValdezHHerpes zoster and tofacitinib therapy in patients with rheumatoid arthritisArthritis Rheumatol201466102675268424943354
   PubMed Web of Science ®Google Scholar
• CurtisJRXieFYunHBernatskySWinthropKLReal-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritisAnn Rheum Dis201675101843184727113415
   PubMed Web of Science ®Google Scholar
• SolomonDHGoodsonNJKatzJNPatterns of cardiovascular risk in rheumatoid arthritisAnn Rheum Dis200665121608161216793844
   PubMed Web of Science ®Google Scholar
• Avina-ZubietaJAThomasJSadatsafaviMLehmanAJLacailleDRisk of incident cardiovascular events in patients with rheumatoid arthritis: a metaanalysis of observational studiesAnn Rheum Dis20127191524152922425941
   PubMed Web of Science ®Google Scholar
• Charles-SchoemanCHWickerPGonzalez-GayMACardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitorSemin Arthritis Rheum201646326127127443588
   PubMed Web of Science ®Google Scholar
• CurtisJRLeeEBKaplanIVTofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeAnn Rheum Dis201675583184125902789
   PubMed Web of Science ®Google Scholar
• ManeiroJRSoutoaAGomez-ReinoaJJRisks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysisSemin Arthritis Rheum201747214915628284845
   PubMed Web of Science ®Google Scholar
• CurtisJRLeeEBMartinGAnalysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programmeClin Exp Rheumatol201735461462228240592
   PubMed Web of Science ®Google Scholar
• Schulze-KoopsHStrandVNduakaCHAnalysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase III and long-term extension studiesRheumatology2017561465728028154
   PubMed Web of Science ®Google Scholar
• RieseRJKrishnaswamiSKremerJInhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomesBest Pract Res Clin Rheumatol201024451352620732649
   PubMed Web of Science ®Google Scholar
• SoutoASalgadoEManeiroJRMeraACarmonaLGomez-ReinoJJLipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysisArthritis Rheumatol201567111712725303044
   PubMed Web of Science ®Google Scholar
• SalgadoEManeiroJRCarmonaLGomez-ReinoJJSafety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and metaanalysisAnn Rheum Dis20147387188223599436
   PubMed Web of Science ®Google Scholar
• StrandVKremerJMGrubenDKrishnaswamiSZwillichSHWallensteinGVTofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trialArthritis Care Res (Hoboken)201769459259827565000
   PubMed Web of Science ®Google Scholar
• WallensteinGVKanikKSWilkinsonBEffects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two phase II randomised controlled trialsClin Exp Rheumatol201634343044227156561
   PubMed Web of Science ®Google Scholar
• StrandVvan VollenhovenRFLeeEBTofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase III study of active rheumatoid arthritisRheumatology (Oxford)20165561031104126929445
   PubMed Web of Science ®Google Scholar
• HarnettJGerberRGrubenDKoenigASChenCEvaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. Administrative Claims DatabaseJ Manag Care Spec Pharm201622121457147127882833
   PubMed Web of Science ®Google Scholar
• LouderAMSinghASavernoKPatient preferences regarding rheumatoid arthritis therapies: a conjoint analysisAm Health Drug Benefits2016928493
   PubMed Web of Science ®Google Scholar